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Introduction
In their letter to conference attendees, Drs Timothy
Rebbeck, Fred Kadlubar, and Christine Ambrosone pro-
posed three main questions as aims to be targeted in the
Special Conference. First, what have we learned from
association studies of single nucleotide polymorphisms
(SNPs)? Second, what have we been unable to accom-
plish and why? Finally, what approaches are required to
improve the state of the science?
The conference was aimed primarily at epidemiologists who
are either performing association studies with SNPs and
haplotypes, or who are planning to do so in the near future.
Keynote talks
John D Potter (Fred Hutchinson Cancer Research Institute,
Seattle, WA, USA) and Charles R Cantor (Sequenom, San
Diego, CA, USA) were the keynote speakers. Dr Potter
gave a general introduction to SNPs and haplotypes,
emphasizing that using the haplotype strategy reduces the
amount of genotyping necessary and increases the power
of a study. However, he proposed that most studies con-
ducted today have limited power to detect low penetrance
risk alleles, or complex gene–environment interactions. He
proposed ‘the last cohort’, which would consist of at least
half a million ethnically diverse individuals. Cell lines should
be established and incident tumor samples would need to
be collected. This sort of approach would be able to
answer questions about association in most common dis-
eases and to address various interactions. However, this
approach may still have low power to detect associations
in complex diseases with diverse subtypes.
Dr Cantor presented data from population-based associa-
tion studies, in which he constructed DNA pools to assess
allele frequencies in the case and control groups. The
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Abstract
This American Association for Cancer Research Special Conference brought together scientists with
diverse expertise to address issues related to use of appropriate epidemiological, statistical, and
laboratory methods to study the genetic epidemiology of cancer. Discussions focused on experiences
with association studies using single nucleotide polymorphisms and haplotypes, their limitations, and
what is needed to improve on the current ‘state of the art’. Various studies were presented in different
contexts, ranging from candidate gene studies to whole genome scans, and conducted in prospective
cohorts, case–control studies, and other study designs. Common problems such as determining the
probability that observed associations are false negative or false positive, the potential effects of
admixture, and determining which polymorphisms to examine in which genes and in which populations
were examined. Problems specific to haplotype analysis were discussed, with emphasis on haplotype
block structures and on how to use haplotypes in analysis. Questions were also posed as to
determining the functional relevance of single nucleotide polymorphisms in molecular epidemiology.
Finally, future directions, using specific examples, were addressed.
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pools were then genotyped in whole genome scans using
30,000 to 60,000 markers. This method allows analysis of
the distribution of genotype frequencies between the two
populations. Samples are very carefully separated into dif-
ferent groups, whether this is by case–control status or
even within subsets based on molecular or environmental
descriptions. Then, each pool is genotyped for a panel of
SNPs, covering the entire genome. If any evidence of
association is discovered, then individual samples can be
genotyped to confirm the association.
Current paradigms for SNP studies
Stephen J O’Brien (National Cancer Institute [NCI], Fred-
erick, MD, USA) presented his views on mapping by
admixture linkage disequilibrium as a shortcut to multifac-
torial and complex disease gene discovery. By studying
diseases that exhibit different incidence between ethnici-
ties, in admixed populations linkage disquilibrium may be
extensive around genes associated with the disease.
Choosing suitable genetic markers was a subject touched
upon by both Sholom Wacholder (NCI, Bethesda, MD,
USA) and Joel N Hirschhorn (Children’s Hospital, Boston,
MA, USA). Both presented material showing that good
selection not only of markers but also of diseases in which
to study these markers affects the likelihood that a study
will yield a false-negative or false-positive finding. A
common thread was that associations must be found
repeatedly if they are to be believed, and it is difficult to
determine when enough evidence is enough.
Genetics and population structure in cancer
gene identification
Haplotypes are regarded as important tools not only in
association studies but also in evolutionary biology. Daniel
O Stram (University of Southern California, Los Angeles,
CA, USA) presented current thinking on the use of haplo-
types in association studies, including determining haplo-
type tagging SNPs, or those SNPs that describe all the
haplotypic variation present across a region of the
genome within a particular population.
Population substructure was the topic of discussion for
both Jonathan Pritchard (University of Chicago, Chicago,
IL, USA) and Rick A Kittles (Howard University, Washing-
ton, DC, USA). Given that certain diseases are more
common in some populations than in others, it is possible
that differences between cases and controls in the mix of
ethnicities can lead to spurious associations. By analyzing
markers that differ between ethnicities, but are not likely to
be associated with disease, it is possible to detect the
degree of confounding by ethnicity, or population stratifi-
cation, that is present in a study.
David Balding (Imperial College, London, UK) presented
the idea of using haplotypes in fine-scale mapping of
disease susceptibility loci. This is accomplished by recon-
structing the evolutionary history of the haplotypes in the
case population. Although these methods are becoming
more computationally feasible, they are still very computer
intensive. Future directions include multistage designs to
combine information from haplotype tagging SNP selec-
tion and the full case-control study, incorporation of block
structures of haplotypes and their inherent uncertainty,
allowing for population structure, and combining associa-
tions and sharing of genetic variation between phenotype.
Applying high throughput SNP technology to
epidemiologic studies
SNP assays must be carefully designed because, as Dr
Meredith Yeager (NCI, Gaithersburg, MD, USA) pointed
out, adjacent SNPs may exist in the region of a targeted
SNP that may interfere with primer or probe hybridization
and cause misclassification of results. Once SNPs are
selected, they must be genotyped in large numbers of
samples. Dr Stephen Chanock (NCI, Gaithersburg, MD,
USA) described his experience running a core genotyping
facility. Robotics and laboratory information management
systems are essential to limit errors in sample handling
and processing, as well as in data collection and manage-
ment. As a collaborating site in the HapMap project, Dr
Stacey Gabriel (Whitehead Institute, Cambridge, MA,
USA) applies high throughput technology in genotyping,
and described genotyping platforms applicable to the
large sizes of studies currently being proposed.
One method of reducing time and cost of whole genome
association studies is to pool samples together, as pre-
sented by Eric Lai (GlaxoSmithKline, Research Triangle
Park, NC, USA). By creating well defined pools, allele fre-
quencies for hundreds of samples can be determined, and
case prevalence compared with control prevalence. Care
must be taken to have homogeneous samples within a
pool, in order to limit error. Although pooling could be a
good screening tool for determining candidate regions or
SNPs for disease association, it is limited because of the
rigidity of pools. For instance, it would be difficult to
remove one or more individuals from a pool because they
changed phenotype or withdrew consent to be included in
a study.
Pak Sham (Social, Genetics and Developmental Psychia-
try Research Centre, Institute of Psychiatry, King’s
College, London, UK) also pointed out that pooling
samples constitutes an initial screen and can not replace
individual genotyping. Also, accurate DNA quantification is
essential to ensure that each individual is equally con-
tributing allele information to the entire pool.
Strategies for selecting SNPs and haplotypes
dbSNP (http://www.ncbi.nlm.nih.gov/SNP) is one of the
main repositories of SNP information on the internet.3
Stephen Sherry (National Center for Biotechnology Infor-
mation, Bethesda, MD, USA) presented its content. The
database is searchable and can be downloaded in its
entirety if so desired. Obvious candidate SNPs to study
would be those that regulate gene expression. Allelic
imbalance, or unequal expression of allelic transcripts,
could provide evidence of this. Thomas Hudson (McGill
University Health Centre, Montreal, Quebec, Canada)
described how polymorphisms that effect splicing of
mRNA or transcription/translation of the gene product
could be responsible for such an effect, as well as those
that alter mRNA or protein stability. SNPs creating allelic
imbalance are of added interest, considering that they may
alter the possibility that a SNP that changes some aspect
of protein function is not be expressed, therefore poten-
tially negating its effect.
One factor effecting the selection of SNPs to study is
allele frequency. A common theory in genetic epidemiol-
ogy is that risk for common disease is associated with
common alleles. Gilles Thomas (Centre d’Etude du Poly-
morphisme Humain [CEPH], Paris, France), proposed that
this may not always hold true, especially in instances
where a large number of rare SNPs in one gene convey
risk for disease.
A previously mentioned tool that could prove useful in
selecting SNPs to use in studies would be to focus on
those that differ in allele frequency between populations.
These are SNPs that may have been under some sort of
evolutionary selective pressure and therefore alter some
aspect of disease risk. Anthony Brookes (Karolinska Insti-
tute, Stockholm, Sweden) has been cataloguing these
SNPs. He is also finding that ‘duplicons’ (regions of the
genome that are either exactly repeated or are highly
homologous to other regions) can give rise to spurious
interindividual variation. Increasing the complexity is the
possibility that interindividual variation (polymorphisms)
can indeed occur in such regions, but because of duplica-
tion an individual could have other than the normal one or
two copies of a particular sequence. Carefully designed
assays can determine the cause of variation seen in dupli-
cons once they are known to be present.
Determining the functional relevance of
human SNPs in molecular epidemiology
Only a small fraction of the many tens of thousands of
genes already discovered in the human genome have a
known function. Considering this, determining the effect
on gene function or regulation for all of the SNPs in those
genes have is a truly daunting task. Tim Hubbard
(Welcome Trust Sanger Institute, Cambridge, UK)
described the Ensembl database, which is designed to
draw together information from many sources and auto-
matically annotate gene function and the variation present
in each gene.
Although determining the functional significance of SNPs
in proteins in general is not straightforward, it can be con-
siderably easier for those genes involved in drug metabo-
lism. Genetic variation in drug metabolism was known
before the genes actually encoding the responsible
enzymes were discovered. The field of pharmacogenomics
addresses the issues of such variation and hopes to
describe the interindividual differences in response to
therapeutic drugs. Additionally, genetic differences
between tumors can affect the way in which cancer
responds to therapy. Richard Weinshilboum (Mayo
Medical School, Mayo Clinic, Rochester, MN, USA)
described the history of genetic polymorphisms in genes
related to drug metabolism, specifically the sulfotrans-
ferase enzymes. William E Evans (St. Jude Children’s Hos-
pital, Memphis, TN, USA) discussed differences in
response to chemotherapy in acute lymphoblastic
leukemia. Gareth Morgan (University of Leeds, Leeds, UK)
reported that personalized medicine is coming, taking into
consideration germ line (inherited) or tumor (somatic)
mutations that determine response to a particular treat-
ment, and that side effects as well as end-points and sur-
vival must be taken into consideration when designing
clinical studies.
Future directions for SNPs, haplotypes, and
cancer
Specific examples of large epidemiological studies relat-
ing SNPs and haplotypes to cancer were presented by
Nat Rothman (NCI, Bethesda, MD, USA) and David
Hunter (Harvard School of Public Health, Boston, MA,
USA). The Interlymph Study (non-Hodgkins lymphoma)
and the NCI Breast and Prostate Cancer Cohort Consor-
tium are two of the largest, most ambitious cohort studies
ever undertaken. Both aim to tackle the problems of deter-
mining gene–environment interaction by increasing
sample size. This increase is carried out by collaborations
with many centers, each with comparable data sets, within
the framework of prospective cohorts.
Daniela Seminara (NCI, Bethesda, MD, USA) presented
the funding mechanisms at the NCI specifically for collab-
oration between groups under the Epidemiology and
Genetics Research Program. The main purpose of the
NCI in these endeavors is to not only provide monetary
support but also to provide support in building the infra-
structure necessary to carry out such large collaborations
successfully.
DeCode Genetics Inc, (Reykjavik, Iceland) has been col-
lecting and genotyping individuals from Iceland with
various outcomes, including cancers, and comparing the
data with those from healthy individuals. Because of its
history of isolation and good record keeping, the geneal-
ogy of most people in Iceland is known, and detailed
family trees can be drawn. Although this approach will be
Available online http://breast-cancer-research.com/content/6/2/E94
useful in detecting risk alleles in the population of Iceland,
the probability that any risk alleles will be due to founder
effect is fairly high, and therefore they may be of limited
significance outside Iceland.
Conclusion
The conference ended with a great feeling of success.
Those who had little or no experience and exposure to use
of SNPs and haplotypes in epidemiology came away with
a better understanding of how to go about setting up such
studies, and how to interpret studies in the literature. The
substantial methodologic difficulties existing in this area
were outlined and guidelines were laid out, fueled in part
by recent collaborations such as Interlymph and the NCI
Cohort Breast and Prostate Cancer Consortium, on how
to design, conduct, and analyze data from large, collabora-
tive efforts.
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